Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
348 studies found for:    APOA1
Show Display Options
Rank Status Study
1 Completed Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients
Condition: Diabetes
Interventions: Drug: Rosuvastatin;   Drug: Placebo
2 Unknown  Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes
Condition: Type 2 Diabetes Mellitus Without Insulin Treatment
Interventions: Drug: simvastatin/ezetimibe;   Drug: atorvastatin 20mg
3 Completed Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Rosuvastatin;   Drug: Atorvastatin
4 Completed Resveratrol and Serum Apo A-I
Condition: Dyslipidemia
Intervention: Dietary Supplement: Resveratrol capsules
5 Completed Theobromine, Vascular Function and Intestinal apoA-I Production
Condition: Cardiovascular Disease
Interventions: Dietary Supplement: Theobromine;   Dietary Supplement: Placebo drink
6 Completed The Effects of Fat and Theobromine on apoA-I
Condition: Cardiovascular Diseases
Interventions: Dietary Supplement: Fat milkshake;   Dietary Supplement: Theobromine
7 Completed
Has Results
Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
Condition: Dyslipidemia
Interventions: Drug: Atorvastatin;   Drug: ABT335;   Drug: ER Niacin
8 Recruiting Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
9 Completed
Has Results
ROMEO (Rosuvastatin in Metabolic syndrOme)
Condition: Metabolic Syndrome X
Interventions: Drug: Rosuvastatin;   Drug: Atorvastatin
10 Unknown  Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)
Condition: HDL Cholesterol
Interventions: Drug: Simvastatin;   Drug: Atorvastatin 80 mg
11 Completed Apolipoprotein A-I Gene Polymorphism and Atherosclerosis
Conditions: Coronary Arteriosclerosis;   Cardiovascular Diseases;   Heart Diseases;   Atherosclerosis
Intervention:
12 Completed ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
Condition: Coronary Artery Disease
Interventions: Drug: RVX000222;   Drug: Placebo RVX000222
13 Terminated Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL
Condition: Dyslipidemias
Interventions: Drug: Nicotinic acid;   Drug: Placebo
14 Completed Propofol and Perioperative Inflammation
Condition: Inflammation
Interventions: Drug: propofol;   Drug: Intralipid 10%;   Drug: Saline
15 Completed Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease
Conditions: Atherosclerosis;   Coronary Artery Disease
Interventions: Drug: RVX000222;   Drug: Placebo
16 Completed An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects
Conditions: HIV Infections;   Metabolism, Lipids
Intervention: Drug: nevirapine
17 Terminated High Density Lipoprotein Turnover
Condition: Obesity
Interventions: Drug: Placebo;   Drug: Rimonabant
18 Unknown  Group Motivational Intervention in Overweight/Obese Patients
Conditions: Overweight;   Obesity
Intervention: Behavioral: Motivational intervention
19 Completed Effect of Abdominal Obesity on Lipoprotein Metabolism
Conditions: Obesity;   Dyslipidemia;   Insulin Resistance
Intervention: Behavioral: Weight loss by dietary restriction
20 Completed A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome
Conditions: Metabolic Syndrome;   Dyslipidemia
Intervention: Drug: Rosuvastatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.